15 February 2022 – The Swiss federal government has signed a contract with GlaxoSmithKline AG to reserve a promising medication called the Monoclonal Antibody Sotrovimab for treating COVID-19. This is the third contract of this type concluded with the company since the outbreak of the COVID-19 pandemic.

For more information, see here.